What exactly did RBC Capital change for Kymera on Feb 26 2026?

RBC Capital **maintained an Outperform** rating for Kymera and **raised the price target to $108** on Feb 26, 2026. The note was logged at 11:56 AM and produced a small market move of 0.15% ($0.14).

How should I use the KYMR analyst rating in my investment decisions?

Use the **KYMR analyst rating** as one input among valuation, clinical catalysts, and risk. An Outperform signals relative upside expectations, but verify with cash runway, trial readouts, and possible dilution from the ATM offering.

Does the price target change mean immediate upside for the stock?

A price target change indicates analyst views, not a guarantee of immediate gains. Market reaction depends on whether the update alters expectations beyond what the market already priced, and on corporate actions like the ATM program.

What key events could make the KYMR analyst rating change again?

Major clinical readouts, regulatory milestones, quarterly results that alter guidance, balance sheet shifts from capital raises, or material insider transactions can all prompt analysts to revisit the **KYMR analyst rating**.

Analyst Ratings

KYMR: Kymera Therapeutics Maintained Outperform by RBC Capital Feb 26 2026

ByHuzaifa Zahoor February 27, 2026February 27, 2026

RBC Capital maintained an Outperform rating on Kymera Therapeutics (KYMR) on February 26, 2026. This KYMR analyst rating action included a price target increase to $108, according to StreetInsider, and registered a small intraday move of 0.15% ($0.14). The firm listed the call at 11:56 AM ET. Kymera’s market cap stands at $7,602,307,441, and investors should weigh the rating against recent company activity, including an ATM offering and insider sales. Meyka AI rates KYMR with a grade of B+.